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A B ST R A C T
The purpose o f  the present study was to dynam ically analyze the role o f  antiphospholipid syndrom e in pa­
tients with acute disturbances o f  cerebral blood flow. Twenty-eight patients (16 females and 12 males) aged 
between 47 and 61 years were exam ined. The following criteria for patient's incorporation into the study were 
observed: presence o f  a focal neurological deficit, ultrasonographic evidence o f disturbed cerebral blood flow, 
CT or MRI data about brain stroke. According to the data from the clinical or x-ray exam ination, the patients 
w ere divided into three groups: with hem orrhagic, embolic, or throm botic stroke. Anticardiolipid (aCL) anti­
bodies were assessed by ELISA method for a 12-month period. Elevated titres o f aCL antibodies w ere proved 
in 12 patients (in 43 per cent o f  the cases) - in ten with ischem ic and in two - with hemorrhagic stroke. The 
treatm ent with neuroprotective, antiaggregation and im m unom odulatory means resulted in im provem ent of 
the clinical sym ptom s and antiphospholipid syndrom e as well. It could be concluded that the sum m arized clin­
ical, roentgenological and im m unological data suggest the involvem ent o f  elevated titres o f  aCL antibodies 
into the pathogenesis o f  the acute cerebral blood flow disorders. The estimation o f these antibodies should be 
considered obligatory in the patients with stroke with a view to enlargem ent o f  the prognostic criteria and 
more adequate therapeutic approach.
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Antiphospholipid antibodies (APA) occur in thromboses, 
fetal abortions and thrombocytopenias being, however, 
most common in systemic lupus eythematodes (SLE) in a 
good correlation with immunoglobulin G (IgG) (5). Some 
authors (6) detect antiphospolipid syndrome (APLS) in 
51,1 per cent o f the cases with arterial thromboses, in 45,6 
per cent o f the cases with deep vein thromboses, and in 37,3 
per cent o f the cases with abortions and still-births. The 
combination o f  APLS and SLE presents with hemolytic 
anemia in 28,6 per cent o f  the cases accompanied by APA. 
These data indicate the necessity o f  the study o f the proba­
ble hypercoagulation state in the patients with acute cere­
bral blood flow disorders ACBFD) and recommend the 
usage of anticoagulation and antiaggregation means with a 
view o f the prevention o f cerebrovascular accidents. Ac­
cording to the therapeutic experience gained by certain au­
thors (2,3,9), the administration o f intravenous immuno­
globulin (1VIG) is related with an increased risk o f compli­
cations in the patients with atherosclerosis, hypertension, 
hyperlipidemia, obesity, myocardial infarction, congestive 
events in cardiovascular insufficiency, diabetic
nephropathy, headache, eruptions, pruritus, fever,
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leukopenia, viral syndromes, acute renal failure, etc. In such 
cases a sharp reduction of the number o f infusions and cor­
rection o f the complications by symptomatic means should 
be recommended.
Anticardiolipid (aCL) antibodies were examined by means 
o f quantitative methods while lupus anticoagulants were 
established indirectly by reading o f the prolonged partial 
thromboplastin time, caolin coagulation time, or RVVT. 
There are interesting reports in the literature available con­
cerning the polyclonal antibodies especially in SLE accom­
panied by an increased risk o f vascular occlusions (8). The 
lupus anticoagulant is an antibody against phospholipids 
that can be proved by means o f coagulation tests. 
Thrombocyte microaggregants can be observed in patients 
with aCL antibodies. However, in APLS patients' plasma 
some complexes can be detected that unlock the cal­
cium-independent thrombocyte aggregation. This fact is of 
importance for the diagnosis, correction, and monitoring of 
A P L b (ll) .
The cerebral microembolization detected through monitor­
ing o f  TS and MES was established in APLS patients and 
correlated with SLE evidence and risk o f a cerebrovascular 
disease (8,10). The comparison o f these facts with the clini­
cal and morphological; manifestations enables the general­
ization that APLS is accompanied by arterial or venous 
thromboses, cardiac valvular anomalies, abortions, 
thrombocytopenia, or cerebrovascular diseasae. The associ-
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ation o f  lupus anticoagulants in the onset o f  epileptic sei­
zures was reported, too.
The aim o f  the present study was to dynamically analyze 
the role o f  APLS in the patients with ACBFD.
M A T E R IA L  AND M E T H O D S
The patients with APLS present with APA of a median or 
high titre and one 'major clinical criterion' such as venous or 
arterial thromboses confirmed by CT or MRI, 
ultrasonography, and histopathology, as well as 
thrombocytopenia or habitual abortions. The study covered 
28 patients, 16 females and 12 males, aged between 47 and 
61 years and without diabetes mellitus, hypertension and 
tobacco smoking. The incorporation o f the patients into the 
trial was performed according to the following 
clinico-laboratory parameters: a) presence of a focal neuro­
logical deficit, b) computer tomography (CT) or magnetic 
resonance imaging (MRI) data about brain stroke and c) 
ultrasonographic evidence o f disturbance of the cerebral 
blood flow. According to the data from the clinical or x-ray 
examination, the patients were divided into three groups: 
with hemorrhagic stroke (2 patients), with embolic stroke 
( 14 patients), and with thrombotic stroke ( 12 patients). aCL 
antibodies were assessed by ELISA method fora 12-month 
period. Values less than 1,1 or less than 20 were considered 
normal. Immunovenin in a single dose o f 250 mg/kg b. m. 
was administered every month for 6 months. A control 
group consisted of 28 patients with similar cerebrovascular 
accidents but without APAs.
R E SU L T S AND D ISC U SSIO N
APLS aberrations were looked for through considering the 
leading neurological syndrome for the pathogenesis o f the 
clinical symptoms based on anamnestic data, results from 
CT, angiographic, electroencephalographic examinations 
and immunological status.
Elevated titres o f aCL antibodies were proved in 12 patients 
(in 43 per cent o f the cases): in ten (36 per cent) with 
ischemic and in two (7 per cent) with hemorrhagic stroke
(Fig- !)■
Electroencephalographic examinations demonstrated dif­
fuse changes o f peak and teta waves with transient foci of 
teta and delta waves in 20 patients. The dynamic monitor­
ing revealed a reduction o f the general-brain and local 
changes in the patients with a favourable outcome of the 
disease.
It is accepted that APAs modify the coagulation status and 
increase the risk o f blood coagulation. These data demon­
strate the necessity of administration o f anticoagulation and 
antiaggregation means with a view o f the prevention o f the 
cerebrovascular accidents. The treatment with 
neuroprotective, antiaggregation and immunomodulatory 
preparations improved the clinical symptoms and normal­
ized the APLS. Similar results were reported by other in­
vestigators, too ( 1,4,7).
The dynamic monitoring o f the patients showed a good in­
fluence upon the immunological status in 58 per cent o f the 
cases presenting with high antibody titres. The antibody 
titres decreased in some patients and even normalized in 
other ones (Fig. 2).
Fig. 2. Therapeutic effect on APA titre
Based on our own data we could conclude that APLS was 
present in most patients with a cerebrovascular disease. 
Some other authors describe similar findings, too. Accord­
ing to Chlenkovska et al. ( ), 32 per cent o f the patients with 
APAs presented with transient ischemic attacks and stroke. 
According to the APASS (1), 58 out o f 108 patients (54,7 
per cent o f the cases) presented with both APLS and stroke.
C O N C L U SIO N
Fig. 1. Percentage ratio o f  patients with ACBFD and 
presence o f  APA
The summarized clinical, roentgenological, 
electroencephalographic and immunological data suggest 
the involvement of elevated titres of aCL antibodies into the 
pathogenesis of ACBFD. The determination o f these anti­
bodies in stroke is obligatory with a view to enlargement of 
the prognostic criteria and more adequate therapeutic ap­
proach.
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